Using AI for Protein Design, Molecules and Drug Discovery

Hello Everyone,
We would like to invite you to our AI in Pharma MeetUp event that would focus on the utilization of AI in Protein (Design), Molecules and Drug Discovery.
Save the date (29 April 2025) for this AI in Biochemistry MeetUp event in Munich (specifically at the address: Luise-Ullrich-Straße 14, 80636 Munich).

Agenda Overview:
6:30 PM - Door Open, Drinks & Networking

7:00 PM - Welcome Introduction

7:10 PM - Talk 1:Reconstructing biological function with de novo protein design
Prof. Dr. Lukas Milles
Gene Center, LMU University Munich
& Max Planck Institute of Biochemistry

7:40 PM - Talk 2: Computational Pathology in Oncology Drug Development
Dr. Christian Eisen
Director Translational Science
AstraZeneca, Munich

8:10 PM - Drinks, Snacks & Networking

Talks Details:

Talk 1
Title: Reconstructing biological function with de novo protein design

Abstract:
De novo protein design has experienced a machine learning-fueled revolution, vastly expanding our ability to design complex and functional proteins beyond those found in nature. I will discuss recent work at the intersection of de novo protein design, deep learning and fundamental biophysics of protein function regarding both computational design and wet lab biophysical characterization. The work will touch upon control over levels of protein structure from oligomeric state and symmetry, down to side chain orientation to control the design of protein-protein interfaces.

Speaker:
Prof. Dr. Lukas Milles
LMU University Munich
& Max Planck Institute of Biochemistry

Biography:
Prof. Dr. Lukas Milles completed his PhD in single-molecule biophysics at LMU Munich with Hermann Gaub in 2018. From 2019-2024 he was a postdoctoral researcher at the Institute for Protein Design with David Baker at the University of Washington in Seattle. Since 2024, he heads the Emmy Noether Research Group Biomolecular Design at the Max Planck Institute of Biochemistry, and holds a professorship (W2) at the Gene Center, Faculty of Chemistry and Pharmacy at LMU Munich.

Talk 2
Title: Computational Pathology in Oncology Drug Development

Abstract:
This talk will explore the transformative role of computational pathology in the field of oncology drug development. By leveraging advanced image analysis and artificial intelligence, researchers can enhance the evaluation of tumor biology and improve decision-making processes at various stages of drug discovery and development. The presentation will discuss how computational techniques analyze vast amounts of histopathological data, enabling the identification of viable therapeutic targets and more accurate assessments of patient responses. Additionally, case studies will illustrate the integration of computational pathology into clinical workflows, demonstrating its potential to streamline research processes, reduce costs, and ultimately expedite the delivery of innovative cancer therapies to market. Attendees will gain insights into how these cutting-edge methodologies are shaping the future of cancer treatment while fostering a cross-functional collaboration among pathologists, oncologists, and data scientists in the fight against cancer.

Speaker:
Dr. Christian Eisen
Director Translational Science
AstraZeneca, Munich

Biography:
Dr. Christian Eisen is a clinical and translational researcher with a focus on oncology and cell therapy. His career encompasses roles at leading pharmaceutical companies such as Novartis and Bristol-Myers Squibb, where he has played a key part in advancing innovative therapies. Dr. Eisen earned his Ph.D. from the University of Heidelberg, specializing in pancreatic cancer research, and holds a diploma in bioinformatics from TU and LMU Munich. His work effectively bridges scientific research and clinical application, reflecting his dedication to improving patient care.
Currently, as Director of Translational Science and Strategic Partnerships at AstraZeneca Computational Pathology Munich, Dr. Eisen drives the development and implementation of computational pathology driven biomarkers to aid oncology drug development and patient stratification. As a scientific and business leader, he cultivates strong partnerships with external scientific, medical, and regulatory communities, actively engaging with health authorities to shape policy and drive progress in oncology.